WO2001056657A1 - Illuminateur medical - Google Patents

Illuminateur medical Download PDF

Info

Publication number
WO2001056657A1
WO2001056657A1 PCT/JP2001/000381 JP0100381W WO0156657A1 WO 2001056657 A1 WO2001056657 A1 WO 2001056657A1 JP 0100381 W JP0100381 W JP 0100381W WO 0156657 A1 WO0156657 A1 WO 0156657A1
Authority
WO
WIPO (PCT)
Prior art keywords
light
blood flow
irradiation
monochromatic
irradiation device
Prior art date
Application number
PCT/JP2001/000381
Other languages
English (en)
Japanese (ja)
Inventor
Keisuke Kobayashi
Katsuya Nagai
Yoshiko Kobayashi
Original Assignee
Japan Science And Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science And Technology Corporation filed Critical Japan Science And Technology Corporation
Publication of WO2001056657A1 publication Critical patent/WO2001056657A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment

Definitions

  • the present invention relates to an apparatus for flashing and irradiating a local portion of a living body with visible light having a limited wavelength, and enhances the therapeutic effect of various diseases by increasing the local blood flow of the living body.
  • the present invention has been made in view of the above circumstances, and provides a light irradiation device for a living body capable of increasing a blood flow at an irradiation site and exerting a therapeutic effect by blinking irradiation of light having a wavelength having a blood flow promoting action.
  • the purpose is to:
  • a living body light irradiation device comprising: means for obtaining monochromatic light; means for interrupting the monochromatic light; and means for irradiating a part of the living body with the monochromatic light, wherein the monochromatic light is limited.
  • the visible light having the lowest energy by the means for interrupting the monochromatic light to increase local blood flow.
  • FIG. 1 is a schematic view of a living body light irradiation device showing an embodiment of the present invention.
  • FIG. 2 is a diagram showing an example of a temporal change of a blood flow due to light irradiation on a lamp obtained using the living body light irradiation device according to the embodiment of the present invention.
  • FIG. 3 is a diagram showing an example of measuring the wavelength dependence of the blood flow increase rate at an irradiation density at which the decrease in the blood flow increase rate is not so large in the embodiment of the present invention.
  • Figure 4 is, L-N a G MMA was measured diluted to give the group (5 mice) and controls group administered only PBS (five) of each individual rat blood flow changes about with PBS, and each It is a figure which shows the average blood flow change waveform obtained by averaging in the group.
  • FIG. 5 is a configuration diagram of a catheter-type irradiation device showing another embodiment of the present invention
  • FIG. 6 is a schematic diagram of an irradiation panel of another irradiation device.
  • FIG. 6 is a schematic view of an irradiation panel of another irradiation apparatus.
  • FIG. 7 is a configuration diagram of an irradiation apparatus using a narrow band filter according to another embodiment of the present invention.
  • the inventors of the present application have been interested in the therapeutic effect of visible light for a long time, and as a subject themselves, as a result of the measurement of the irradiation of visible light to the forearm flexor lateral skin] I with a Doppler blood flow meter, It was confirmed that it increased the blood volume (equivalent to blood volume) in the skin at the site.
  • a three-year specific study has been undertaken to start a collaborative study using rats to make this study more scientific. An experiment using the animal showed that when visible light was flashed on the rat's tail (lighting on and off for 3 seconds), the blood flow at the tail-irradiated site increased when the light was on and off, respectively. Obtained.
  • N 0 S nitric oxide synthase
  • LN G MM A LN G mo n ome thyl- L- arginineacetate
  • NOS nitric oxide synthase
  • NOS may be activated by visible light. Since the combined NOS absorption has an absorption maximum at 436 nm instead of 420 nm, the former theory of NO release from storage factors is more likely. It has been confirmed that the flashing of visible light on the forearm flexor side skin of the human also causes an increase in blood flow when it is turned on and off, similarly to the irradiation on the tail of the rat.
  • FIG. 1 is a schematic view of a light irradiation device for a living body showing an embodiment of the present invention.
  • a 500 W Xe lamp or a light emitting diode
  • a spectroscope 3 to obtain monochromatic light.
  • the monochromatic light passes through a mechanical shutter 4 of an electromagnetic opening and closing type and an ND filter 15 for adjusting the amount of light, and is then irradiated to the central part 9 of the tail of the rat 8 by a lens 6 and a plane mirror 7.
  • the probe 11 of the laser Doppler blood flow meter 10 is brought into contact with the central part 9 of the irradiated tail so as not to apply a load.
  • the mechanical shutter 4 is driven at a 1: 1 opening / closing ratio (opening 3 seconds, closing 3 seconds) by a shutter driving device 14 connected to the timer 15, and the opening / closing signal and the blood flow signal are used.
  • the AZD converter 16 converts the AZD and imports it to the computer 17.
  • reference numeral 12 denotes a counter balance of the probe 11
  • reference numeral 13 denotes a narrow band pass filter
  • reference numeral 18 denotes a light shield.
  • the light irradiation period (open) and the non-irradiation period are calculated by arithmetically averaging the blood flow signal assumed for a sufficiently long time (about 600 seconds) continuously in synchronization with the opening and closing of the mechanical shutter 4.
  • the time change of the blood flow at (closed) can be derived.
  • This averaging operation eliminates noise and other changes that are not synchronized with the opening and closing of the shutter. Adequate attention is paid to the rat using a light shield or the like so as not to give an auditory stimulus due to visual stimulation or shutter opening / closing noise.
  • FIGS. 2 (a) and 2 (b) show an example of a temporal change in blood flow due to light irradiation in the rat thus obtained.
  • Wavelength of the irradiated light is changing the power density of the irradiation light at 5 7 5 nm 0. 1 9 8 mW / cm z or al 1.4 9 in the range of mWZ cm 2.
  • the vertical axis represents the blood flow increase rate per power density when the blood flow value immediately before the shutter is opened is 100.
  • the horizontal axis is the time in milliseconds, and the arrow indicates the time when the shutter is opened or closed.
  • Fig. 2 (b) shows the blood flow change during the non-irradiation period.
  • the vertical axis indicates the average value of the blood flow increase rate during the irradiation period.
  • the rate of increase in blood flow shows a strong peak at 410-420 nm, and a doublet peak at 540-550 nm and 570-580 nm that is one order of magnitude less.
  • This working spectrum is remarkably similar to the optical absorption spectrum of the six-coordinate Fe + + heme in the low spin state [Ref. (1): Perutz, M. eta 1.I nfluenceof G 1 obin S nestturesonthe Stateofthe Heme. J. Biol. Chem., 253, 350 9-35 16 (1978)].
  • the peak position of the absorption spectrum of NO-myoglobin which is a typical low-spin 6-coordinate Fe ++ heme compound, and the relative value of the absorption coefficient are indicated by the thick solid line in the figure. Is shown.
  • NO the key substance in vasodilation, is involved in this light-induced increase in blood flow.
  • L- NG MMA diluted with PBS (5 animals) and PBS-only control group (5 animals) were measured for individual rat blood flow changes and averaged within each group.
  • the obtained average blood flow change waveforms are shown in FIGS. 4 (a) and (b).
  • the irradiation wavelength is 575 nm.
  • Figure 4 (a) is a white circle control group bloodstream change in illumination period, black circles are the data of the L-N 6 MM A administration group. Error bars indicate standard error.
  • Figure 4 (b) is also open circles control group in the bloodstream change in the non-irradiation period, a black circle represents the data of the L -N G MMA administration group.
  • This NO-hemoglobin concentration is determined by the balance between local NO production and consumption. It is thought that it is. Therefore, it is thought that as the local NO-hemoglobin is consumed by light irradiation, the free NO concentration increases and the blood flow increase rate decreases. When irradiation stops, NO production again exceeds that of NO- ⁇ > moglobin.
  • L one N e MMA is the concentration of the results in N 0- hemoglobin because you inhibit NO synthesis decreases in NO synthase (NO S), also reduced N 0 out release due accordance connexion light irradiation.
  • a specific wavelength light that is, visible light having wavelengths of ⁇ 10% of each of 420 nm, 540 nm, and 575 nm
  • the local blood flow is obtained.
  • a specific wavelength light that is, visible light having wavelengths of ⁇ 10% of each of 420 nm, 540 nm, and 575 nm
  • the cause is the release of nitric oxide from hemoglobin and the like bound to nitric oxide based on its wavelength characteristics.
  • a continuous wavelength light source such as a xenon lamp
  • a spectroscope + a shutter are used.
  • FIG. 5 is a configuration diagram of a catheter-type irradiation device showing another embodiment of the present invention
  • FIG. 6 is a schematic diagram of an irradiation panel of another irradiation device.
  • reference numeral 20 denotes a microphone intensity processor for controlling the light emission intensity of the LED and 0 n-0 ff modulation (MP), 21 to 23 are power supplies (P 1 to P 3), and 24 is a light source having a wavelength of LED (D 1), 25 is LED (D 2) of 540 nm wavelength light, 26 is LED (D3) of 575 nm wavelength light, 27, 29 are optical fiber bundles, 28 are light mixing
  • the mixing device 30 is an irradiation device as an irradiation jig. As shown in Fig. 6, three types of LEDs 31 to 33 of 415 nm, 540 nm, and 575 nm are arranged in a hexagonal unit (set of LEDs) 34 as one unit.
  • the intensity of 0n-0ff is modulated by the micro processor (MP) as in Fig. 5.
  • the LED that lights up in accordance with the surface area of the irradiation area is selected in the hexagonal unit 34 described above.
  • LEDs not only the three types of LEDs of 4 15 nm, 540 nm, and 5 75 nm, but also the application of combining LEDs with a peak near 150 nm is basically the same as in FIGS. 5 and 6. Can be. Further, although not shown, a tungsten filament bead ball and a band pass filter of 1450 nm may be combined instead of the near infrared LED.
  • a narrow band filter that passes only light of a specific wavelength (for example, 575 nm) may be used instead of the spectroscope.
  • FIG. 7 is a configuration diagram of an irradiation apparatus using a narrow band filter according to another embodiment of the present invention.
  • a lamp (halogen, metal halide, etc.) 42 serving as a light source is placed at the center of the dichroic spherical mirror 41, and the heat ray component of the light emitted from the lamp 42 backward is directly applied to the rear. Only the visible light component is focused at the position of the lamp 42. The light beam emitted forward from the position of the lamp 42 set in this way is converted into parallel light by the lens 43, and only visible light is transmitted forward by the heat ray absorption or reflection type heat ray filter 44. .
  • a bandpass filter 45 that transmits only light with a bandwidth of ⁇ 10% centered on one of 575 nm, 545 nm, and 420 nm is used as a single color of any of the above three types. Get light.
  • the bandpass filter 45 may be turret-shaped so that it can be replaced as desired.
  • the monochromatic light beam is intermittently modulated at a predetermined frequency by a shutter 46, is once condensed by a lens 47, and is again given an arbitrary spread by a lens 48.
  • the shutter 46 may be mechanical or liquid crystal.
  • the lens 48 is movable with respect to the lens 47 to adjust the light distribution on the irradiation surface 50.
  • the above-mentioned irradiation light can change the intermittent force and the on-off ratio of the intermittent light.
  • the 0n-0ff ratio is set in the range of 1: 1 to 1 (on): 1100 (off). The reason is that if the amount of irradiation increases when the blood flow is small, the N 2 O in the blood flow will be exhausted and the effect will be lost even if the light is applied for a longer time. In other words, while the light is cut off, a new blood flow flows into the irradiation area and is supplied with N 0 force again. The balance between irradiation time and waiting time differs depending on the irradiation site.
  • the biological light irradiating device of the present invention emits visible light with the lowest energy using a limited wavelength, and is effective without harming the living body due to the irradiation. It is possible to increase the local blood flow to the skin, and to improve wound healing, diseases causing peripheral circulatory insufficiency (such as atherosclerotic vascular occlusion), and improvement by increasing blood flow. It can also be used for non-invasive treatment of diseases such as liver disease. It should be noted that the present invention is not limited to the above embodiments, and various modifications are possible based on the spirit of the present invention, and they are not excluded from the scope of the present invention. As described above, according to the present invention, the following effects can be obtained.
  • the blinking irradiation of light having a wavelength having a blood flow promoting action can increase the blood flow at the irradiation site and exert a therapeutic effect.
  • Clinically expected therapeutic effects by improving blood flow include the following diseases in addition to promoting wound healing of trauma and surgical wounds.
  • the above diseases are caused by arteriosclerosis, diabetes, which causes myocardial infarction, which is considered to be one of the lifestyle-related diseases, and peripheral blood flow insufficiency due to unknown causes.
  • the disease causes stiffness, cold feeling, gangrene, etc.
  • the living body light irradiation device may It is unique in that it is intended for use in diseases for which a therapeutic effect is expected due to an increase in NO.
  • Conventional solar devices generate heat, and it is impossible to irradiate for a long period of time to generate fatigue and give a fatigue feeling to a person to which the heat is applied.
  • the device has the advantage that it uses very little heat, is prolonged without fatigue, and can cause increased blood flow.
  • the living body light irradiation device is capable of treating peripheral diseases such as wound treatment and peripheral circulatory insufficiency (arteriosclerotic vasculature) without local harm by irradiating low-energy visible light with local blinking. It is suitable for use as a device for non-invasive treatment of diseases such as obstruction, which are improved by increased blood flow (such as liver disease).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

L'invention concerne un illuminateur biomédical conçu pour augmenter le débit volume de sang dans la partie illuminée, par clignotement d'une lumière à une longueur d'onde accélérant le débit sanguin, de sorte qu'un effet curatif soit obtenu. Ledit illuminateur biomédical comprend une source lumineuse (1), un spectroscope (3) pour la production d'une lumière monochromatique à partir de la lumière produite par la source lumineuse (1), un obturateur (4) pour l'interception de la lumière monochromatique, et des moyens pour illuminer une partie d'un organisme avec la lumière monochromatique. La lumière monochromatique est une lumière à longueur d'onde limitée. Le débit-volume de sang dans une partie locale est augmentée par le clignotement d'une lumière visible de faible énergie, au moyen de l'obturateur (4).
PCT/JP2001/000381 2000-02-01 2001-01-22 Illuminateur medical WO2001056657A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000023767A JP4376404B2 (ja) 2000-02-01 2000-02-01 生体用光照射装置
JP2000-23767 2000-02-01

Publications (1)

Publication Number Publication Date
WO2001056657A1 true WO2001056657A1 (fr) 2001-08-09

Family

ID=18549879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/000381 WO2001056657A1 (fr) 2000-02-01 2001-01-22 Illuminateur medical

Country Status (2)

Country Link
JP (1) JP4376404B2 (fr)
WO (1) WO2001056657A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4257294B2 (ja) * 2002-09-20 2009-04-22 株式会社バイオテック ヘッドフォン型育毛補助装置
JP4425593B2 (ja) * 2003-09-26 2010-03-03 テルモ株式会社 穿刺器具および穿刺器具用光照射装置
WO2005077458A1 (fr) * 2004-02-13 2005-08-25 Fancl Corporation Procédé de maquillage et d'embellissement utilisant la chimiluminescence, agent lumineux pour l'embellissement par irradiation de la peau et maquillage/matériel d'embellissement
JP2005224502A (ja) * 2004-02-16 2005-08-25 Terumo Corp 光照射装置
JP2007091673A (ja) * 2005-09-29 2007-04-12 Toshiba Corp 血液循環促進剤、血液循環装置および血液循環促進医療システム
US9149646B2 (en) * 2008-12-31 2015-10-06 Koninklijke Philips N.V. Method and apparatus for controlling a process of injury therapy
JP2011161222A (ja) * 2010-01-15 2011-08-25 Alcare Co Ltd 光創傷治療装置

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59177450U (ja) * 1983-05-17 1984-11-27 宮島　一清 光線制御装置
JPH02302276A (ja) * 1989-05-17 1990-12-14 Matsushita Electric Ind Co Ltd 光治療器
JPH08103508A (ja) * 1994-10-05 1996-04-23 Yasuo Hashimoto 癌治療器
JPH0910330A (ja) * 1995-06-27 1997-01-14 Minolta Co Ltd 光線治療装置
JPH0984888A (ja) * 1995-03-23 1997-03-31 Tsutomu Kamei 非侵襲的免疫監視能増強方法及び前頭部パルス光照射用具
JPH11151309A (ja) * 1997-09-19 1999-06-08 Otsuka Pharmaceut Factory Inc 癌抑制装置

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59177450U (ja) * 1983-05-17 1984-11-27 宮島　一清 光線制御装置
JPH02302276A (ja) * 1989-05-17 1990-12-14 Matsushita Electric Ind Co Ltd 光治療器
JPH08103508A (ja) * 1994-10-05 1996-04-23 Yasuo Hashimoto 癌治療器
JPH0984888A (ja) * 1995-03-23 1997-03-31 Tsutomu Kamei 非侵襲的免疫監視能増強方法及び前頭部パルス光照射用具
JPH0910330A (ja) * 1995-06-27 1997-01-14 Minolta Co Ltd 光線治療装置
JPH11151309A (ja) * 1997-09-19 1999-06-08 Otsuka Pharmaceut Factory Inc 癌抑制装置

Also Published As

Publication number Publication date
JP4376404B2 (ja) 2009-12-02
JP2001212250A (ja) 2001-08-07

Similar Documents

Publication Publication Date Title
Barolet Light-emitting diodes (LEDs) in dermatology
KR101239925B1 (ko) 모발 성장 촉진을 위한 방법 및 장치
Oliveira Sampaio et al. Effect of laser and LED phototherapies on the healing of cutaneous wound on healthy and iron-deficient Wistar rats and their impact on fibroblastic activity during wound healing
US20050080465A1 (en) Device and method for treatment of external surfaces of a body utilizing a light-emitting container
US20060217690A1 (en) Method for treating various dermatological and muscular conditions using electromagnetic radiation
WO2006015493A1 (fr) Methode de traitement de tissus cutanes de mammiferes par rayonnement a impulsions en presence d'un compose photoactif
JP2009528853A (ja) 低強度光線療法を使用する座瘡治療のための方法および装置
CA2500961A1 (fr) Appareil de photobiostimulation
CA2251551C (fr) Procede de traitement d'etats pathologiques de tissus a l'aide d'un rayonnement non coherent et dispositif de mise en oeuvre de ce procede
Oh et al. Therapeutic application of light emitting diode: Photo-oncomic approach
Fritsch et al. Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods
Nauta et al. Photodynamic therapy of oral cancer A review of basic mechanisms and clinical applications
Kashiwagi et al. Photobiomodulation and nitric oxide signaling
JP2008188258A (ja) 光線治療装置
WO2001056657A1 (fr) Illuminateur medical
AU778495B2 (en) Tissue rejuvenation by illuminating radiation
JP2017528572A (ja) 放射性高分子マトリクス
Van den Boogert et al. Fractionated illumination for oesophageal ALA-PDT: effect on blood flow and PpIX formation
Gupta et al. Light–tissue interactions
Calderhead Light-emitting diode phototherapy in dermatological practice
US20070276454A1 (en) Apparatus for Illuminating a Zone of Mammalian Skin
Hall et al. Dose response of combination photorejuvenation using intense pulsed light–activated photodynamic therapy and radiofrequency energy
JP2013208331A (ja) 温度調整を伴う光線力学的治療システム
Dierickx Lasers, light and radiofrequency for treatment of acne
Gu et al. Light-emitting diodes for healthcare and well-being

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase